PARP1 and neoplasm: In a recent study, researches combined the PARP inhibitor with CSF-1R blocking antibodies to elucidate the key contribution of immunosuppression to limiting the effective anti-tumor response their study demonstrates that combining the PARP inhibition with macrophage targeting therapy induces a durable reprograming of the tumor microenvironment and can be used as a promising therapeutic strategy for TNBC (Mehta et al., 2021).